Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma remains one of the most aggressive cancers with an ongoing dismal survival rate despite some recent advances in treatment options. This is largely due to the typically late presentation and limited effective therapeutic options in advanced disease. There are numerous circul...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-07-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/9/3/37 |
| _version_ | 1797760034610872320 |
|---|---|
| author | Matthew Loft Belinda Lee Jeanne Tie Peter Gibbs |
| author_facet | Matthew Loft Belinda Lee Jeanne Tie Peter Gibbs |
| author_sort | Matthew Loft |
| collection | DOAJ |
| description | Pancreatic adenocarcinoma remains one of the most aggressive cancers with an ongoing dismal survival rate despite some recent advances in treatment options. This is largely due to the typically late presentation and limited effective therapeutic options in advanced disease. There are numerous circulating biomarkers that have potential clinical application as tumour markers, including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), exosomes and circulating tumour proteins. This review will focus on the development of ctDNA as a non-invasive liquid biopsy, with its high sensitivity and specificity having potential clinical applications in pancreatic cancer. These include a role in screening, prognostication via the detection of minimal residual disease, early detection of recurrence, and for patients with advanced disease; tumour genotyping and monitoring treatment response. Prospective randomised adjuvant clinical trials are currently underway, exploring the impact of ctDNA-guided adjuvant therapy decisions. In this review, we provide perspectives on the current literature and considerations of future directions. |
| first_indexed | 2024-03-12T18:52:58Z |
| format | Article |
| id | doaj.art-d3819f47737e412ca75f541efd5eb77a |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-12T18:52:58Z |
| publishDate | 2019-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-d3819f47737e412ca75f541efd5eb77a2023-08-02T07:06:52ZengMDPI AGJournal of Personalized Medicine2075-44262019-07-01933710.3390/jpm9030037jpm9030037Clinical Applications of Circulating Tumour DNA in Pancreatic AdenocarcinomaMatthew Loft0Belinda Lee1Jeanne Tie2Peter Gibbs3Systems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville 3050, AustraliaSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville 3050, AustraliaSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville 3050, AustraliaSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville 3050, AustraliaPancreatic adenocarcinoma remains one of the most aggressive cancers with an ongoing dismal survival rate despite some recent advances in treatment options. This is largely due to the typically late presentation and limited effective therapeutic options in advanced disease. There are numerous circulating biomarkers that have potential clinical application as tumour markers, including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), exosomes and circulating tumour proteins. This review will focus on the development of ctDNA as a non-invasive liquid biopsy, with its high sensitivity and specificity having potential clinical applications in pancreatic cancer. These include a role in screening, prognostication via the detection of minimal residual disease, early detection of recurrence, and for patients with advanced disease; tumour genotyping and monitoring treatment response. Prospective randomised adjuvant clinical trials are currently underway, exploring the impact of ctDNA-guided adjuvant therapy decisions. In this review, we provide perspectives on the current literature and considerations of future directions.https://www.mdpi.com/2075-4426/9/3/37pancreatic cancercirculating tumour DNA (ctDNA), biomarkersliquid biopsypersonalised oncologytargeted therapyintratumoural heterogeneitymolecular resistance |
| spellingShingle | Matthew Loft Belinda Lee Jeanne Tie Peter Gibbs Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma Journal of Personalized Medicine pancreatic cancer circulating tumour DNA (ctDNA), biomarkers liquid biopsy personalised oncology targeted therapy intratumoural heterogeneity molecular resistance |
| title | Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma |
| title_full | Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma |
| title_fullStr | Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma |
| title_full_unstemmed | Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma |
| title_short | Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma |
| title_sort | clinical applications of circulating tumour dna in pancreatic adenocarcinoma |
| topic | pancreatic cancer circulating tumour DNA (ctDNA), biomarkers liquid biopsy personalised oncology targeted therapy intratumoural heterogeneity molecular resistance |
| url | https://www.mdpi.com/2075-4426/9/3/37 |
| work_keys_str_mv | AT matthewloft clinicalapplicationsofcirculatingtumourdnainpancreaticadenocarcinoma AT belindalee clinicalapplicationsofcirculatingtumourdnainpancreaticadenocarcinoma AT jeannetie clinicalapplicationsofcirculatingtumourdnainpancreaticadenocarcinoma AT petergibbs clinicalapplicationsofcirculatingtumourdnainpancreaticadenocarcinoma |